Imvamune (MVA-BN, marketed as Jynneos in the US and Imvanex in Europe) is approved for use against monkeypox as well as smallpox in Canada and the US (in all other markets it is only used against monkeypox off-label).
Meanwhile, Bavarian Nordic says it continues to secure contracts with other countries, including its home market Denmark, to supply the vaccine to mitigate the current monkeypox outbreak and build stockpiles for future preparedness.
The order with PHAC comes on the back of multiple smallpox vaccine contracts announced by the company last week, as well as a ‘larger vaccine contract’ with another government the week prior (neither the countries, values nor volumes of the deals have been disclosed).
As a consequence of the May orders, it has raised its expectations for FY2022 with revenue now expected to be between DKK 1,400 and 1,600 million (previously between DKK 1,300 and 1,500 million). The contract with PHAC, however, will not start deliveries until 2023 and so will have no additional impact on the company’s financial guidance for 2022.